UnitedHealth Stock Jumps After BofA Upgrade
UnitedHealth stock jumped after Bank of America and peers raised price targets to $450, sparking trader flow that pushed shares to lead the Dow.
KEY TAKEAWAYS
- Bank of America upgraded UnitedHealth to Buy and raised its 12-month price target to $450.
- Shares led the Dow, rising roughly 5–6% following the analyst round of upgrades.
- Analysts cited improving medical-cost trends and AI/utilization tailwinds that could support guidance upside.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
UnitedHealth Group Incorporated (NYSE: UNH) stock surged on June 4, 2026, after Bank of America upgraded the company to Buy and raised its 12-month price target. This move, along with target increases from Morgan Stanley and Truist, helped the shares lead the Dow higher ahead of quarterly results.
Analyst Upgrades and Price Targets
Bank of America raised UnitedHealth to Buy from Neutral and increased its 12-month price target to $450 from $420. Analyst Kevin Fischbeck cited improving medical-cost trends and described the near-term risk-reward into upcoming earnings as favorable. He noted that incoming data made it difficult to attribute first-quarter strength solely to mild flu and weather.
Morgan Stanley maintained an Overweight rating and raised its 12-month price target to $453 from $395. Analyst Erin Wright highlighted emerging signs of softer utilization—lower-than-expected health-care use—that should support managed-care margins. Wright also projected that artificial intelligence (AI) efficiencies could lift earnings per share (EPS) by roughly 45% on average for managed-care peers as these gains scale.
Truist Securities kept a Buy rating and raised its price target to $440 from $395. The firm pointed to favorable first-quarter medical-cost trends, margin recovery in government businesses such as Medicare and Medicaid, and continued strength in the Commercial segment. Truist also noted an upward bias to guidance.
Among analysts covering UnitedHealth, 22 of 28 rate the stock Buy or higher, five Hold, and one Sell. Third-party data characterize the consensus as a Moderate Buy, with an average 12-month price target near $387.
Market Reaction and Fundamentals
On June 4, UnitedHealth shares surged roughly 5–6% intraday after the analyst upgrades, leading the Dow higher amid a mixed market. The stock was already trading higher in pre-market at 9:03 a.m. ET, reflecting early investor response to the research notes.
Company disclosures summarized in coverage show first-quarter revenue of $111.7 billion and adjusted EPS of $7.23, compared with a consensus of $6.61. The board authorized a quarterly dividend of $2.32 per share, payable June 23, 2026, adding a shareholder-return milestone ahead of earnings.
Analysts view the combination of softer utilization signals, improving medical-cost trends, and potential AI-driven efficiencies as creating a more favorable near-term earnings outlook for large managed-care firms. This outlook underpins the recent re-rating and leaves room for guidance upgrades if trends persist into the next quarter.
